Greco 1995.

Methods	RCT
Participants	56 women with advanced cancer either resistant or refractory to initial standard therapy or with an untreated primarily resistant tumour type. Median age in the trial was 57 years (Range: 30 to 73 years). 39 (69%) women had an Eastern Cooperative Oncology Group performance status of 1. Tumour types were as follows: Breast cancer: 17 (30.5%), Non‐small cell lung cancer (NSCLC): 16 (28.5%), Ovarian cancer: 9 (16%), Small cell lung cancer: 5 (9%), Colorectal cancer: 2 (3.5%), Other: 7 (12.5%).
Interventions	Paclitaxel 135 mg/m2 infused as a single dose over 1 hour or divided into 3 doses infused over 1 hour on 3 consecutive days.
Outcomes	Toxicity, objective response.
Notes	There were no serious acute hypersensitivity reactions with either paclitaxel schedule. 7/28 responders had received 1 day schedule 4/28 responders had received 3 day schedule
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Before randomization, patients were stratified according to performance status ... primary disease site, and previous chemotherapy. They were then randomized by a random card system".
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	% analysed for response: 56/56 (100%) "All patients were evaluable for the toxicity assessment ... After two courses, 48 of the 56 patients were evaluable for response. The other eight patients were considered treatment failures".
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists